MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study.
| Image |  |
|---|---|
| Description | scientific article |
| Author/s |
author: Patrice Viens Thomas Bachelot Olivier Chinot Jean-Paul Borg Daniel Birnbaum |
| Publication date | April 1, 2016 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |